Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

This study examined whether response differed between males and females.

Participants were scanned with high-resolution peripheral quantitative computed tomography (HR-pQCT) to measure total volumetric BMD (TtBMD) at baseline, 6, 12, 24, and 36 months.

Who Took Part

According to the abstract, 311 participants were involved.

PubMed tags the participants as both men and women.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Participants were scanned with high-resolution peripheral quantitative computed tomography (HR-pQCT) to measure total volumetric BMD (TtBMD) at baseline, 6, 12, 24, and 36 months.

Balance, physical function, and clinical biochemistry parameters were also assessed.

The subject headings attached to it are Bone Density, Cholecalciferol, Dietary Supplements, Fibroblast Growth Factor-23, Vitamin D and Vitamin D Deficiency.

The authors tagged it with the keywords AGING, BONE QCT/μCT, DUAL X-RAY ABSORPTIOMETRY, DXA, HIGH-RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY and MICROARCHITECTURE.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 311 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2020 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.